University Medical Center Hamburg-Eppendorf | Center for Psychosocial Medicine | Department of Medical Psychology
Hamburg, 20246, Germany
Location status: Recruiting
NCT Number: NCT05959668
Cystinosis is a rare congenital, inherited metabolic disorder that results in the storage of cystine in the cells of many organs of the body. In the infantile nephropathic form of the disease, only the kidney is initially affected by a loss of function, which progresses if untreated and ends in terminal renal failure by early school age. With the prolonged survival of patients due to medication and renal replacement therapy, further loss of function may occur during the course of the disease, especially in the eyes, muscles, endocrine organs and central nervous system.
The quality of life of children with cystinosis is an under-researched topic. The results of the studies available so far show that the young patients and their families report a reduced quality of life and sometimes behavioral problems.
To date, there are no disease specific patient reported outcome measures (PROMs) to measure the quality of life of patients with cystinosis. The aim of the study is to develop a PROM for this target group in several languages (German, English, Spanish and French) from different countries (Germany, United States, Spain, France). The PROM will focus on quality of life and will be developed for children, adolescents, and young adults including parent-report of parents with children aged 0 to 26 years.
Interested in participating?
Request Info8 year–26 year
All sexes
Observational
Hamburg, 20246, Germany
Location status: Recruiting
First, a literature review was conducted to identify relevant quality of life topics for the focus interviews. The development of the cystinosis-specific PROM will include three phases with patient recruitment: (1) focus interviews, (2) pilot-test and cognitive debriefing, and (3) field and re-test.
The questionnaire will be filled out again after two weeks by at least 20% of the patients and parents to assess the test-retest reliability.
The final product will be a psychometrically validated, easy to use, and conceptually appropriate quality of life instrument available in German, English, Spanish, and French for use in research and patient care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
In all study phases, patient recruitment follows these inclusion criteria:
Patients will be asked to participate in the study if they meet the following inclusion criteria:
Exclusion criteria
Time frame: January 2023 - May 2024
Semi-structured interviews are conducted to create a pilot test version of the preliminary disease-specific HrQoL tool (QUALIFY). The results of the qualitative analysis will be used to derive an initial item list and response categories of the preliminary questionnaire.
Time frame: March 2024 - August 2024
A pilot-testing of the preliminary version of the QUALIFY questionnaire, including a cognitive debriefing, are performed, so that young patients and parents report on the comprehensibility, completeness, and cultural applicability of the questionnaire from their perspective.
Time frame: September 2024 - April 2025
A field- and re-test for psychometric assessment of the final version of the QUALIFY questionnaire is performed.
Time frame: May 2022 - April 2025
The 12-item short form of the DISABKIDS Questionnaire is used to assess the HrQoL of children and adolescents with chronic medical conditions from their own as well as their parents' perspectives. The questionnaire consists of three domains: Mental (4 items), social (4 items) and physical (4 items). One composite score can be calculated.
Higher scores indicate better HrQoL.
Time frame: May 2022 - April 2025
For the age group 2-4 years, the generic HrQoL of toddlers is assessed via parent report. It consists of 21 items and describes 4 dimensions (Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning, (5 items), School Functioning (3 items)). The following Scores can be computed: Total Scale Score (21 items); Physical Health Summary Score (8 items); Psychosocial Health Summary Score (15 items).
The 23-item PedsQL™ Generic Core Scales measure generic HrQoL in children, adolescents, and young adults in self-report as well as proxy report. There are four multidimensional scales (Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning, (5 items), School Functioning (5 items)) and three summary scores: Total Scale Score (23 items); Physical Health Summary Score (8 items); Psychosocial Health Summary Score (15 items).
In both versions, scores are transformed to a 0 to 100 scale and higher scores indicate better HrQoL.
Time frame: May 2022 - April 2025
The PedsQL™ Infant Scales measure generic HrQoL in infants aged 1-12 and 13-24 months in proxy report.
The version for infants ages 1-12 months consists of 36 items. There are five multidimensional scales (Physical Functioning (6 items), Physical Symptoms (10 items), Emotional Functioning (12 items) Social Functioning, (4 items), Cognitive Functioning (4 items)).
The version for infants ages 13-24 months consists of 45 items. There are five multidimensional scales (Physical Functioning (9 items), Physical Symptoms (10 items), Emotional Functioning (12 items) Social Functioning, (5 items), Cognitive Functioning (9 items)).
In both versions, scores are transformed to a 0 to 100 scale and higher scores indicate better HrQoL. Three summary scores can be calculated: Total Scale Score (all items); Physical Health Summary Score (using items of Physical Functioning and Physical Symptoms); Psychosocial Health Summary Score (Emotional, Social, and Cognitive Functioning items).
Time frame: May 2022 - April 2025
The 36-item PedsQL™ Family Impact Module describes 8 dimensions: parent self-reported physical functioning (6 items), emotional functioning (5 items), social functioning (4 items), and cognitive functioning (5 items), communication (3 items), worry (5 items), as well as parent-reported family daily activities (3 items) and family relationships (5 items).
Scores are transformed to a 0 to 100 scale. Higher scores indicate better functioning.
Three summary scores can be calculated: Total Scale Score (36 items); Parent HrQoL Summary Score (20 items); Family Functioning Score (8 items).
Time frame: September 2024 - April 2025
The newly developed QUALIFY questionnaire will assess disease-specific HrQoL of young people living wiht cystinosis.
Higher scores will indicate better HrQoL.
Contact information is provided by the study sponsor or research team.
Julia Hannah Quitmann, PD Dr.
CONTACT
Katharina Hohenfellner, PD Dr. med.
CONTACT
Cystinose Stiftung
Other
Development of a Patient-reported Outcome to Measure the Health-related Quality of Life of Children, Adolescents and Young Adults With Cystinosis.
Acronym: QUALIFY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00359684
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystinosis
Bethesda, Maryland, United States
View Trial DetailsNCT05901077
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystinosis
Paris, Île-de-France Region, France
View Trial DetailsNCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial DetailsNCT06065852
AH Amyloidosis, AHL Amyloidosis
Bristol, South West, United Kingdom
View Trial Details